6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
* O
The O
most O
common O
adverse O
reactions O
reported O
in O
> O
=5 O
% O
of O
patients O
simultaneously O
started O
on O
sitagliptin O
and O
metformin O
and O
more O
commonly O
than O
in O
patients O
treated O
with O
placebo O
were O
diarrhea O
, O
upper O
respiratory O
tract O
infection O
, O
and O
headache O
. O

( O
6.1 O
) O
* O
Adverse O
reactions O
reported O
in O
> O
=5 O
% O
of O
patients O
treated O
with O
sitagliptin O
in O
combination O
with O
sulfonylurea O
and O
metformin O
and O
more O
commonly O
than O
in O
patients O
treated O
with O
placebo O
in O
combination O
with O
sulfonylurea O
and O
metformin O
were O
hypoglycemia O
and O
headache O
. O

( O
6.1 O
) O
* O
Hypoglycemia O
was O
the O
only O
adverse O
reaction O
reported O
in O
> O
=5 O
% O
of O
patients O
treated O
with O
sitagliptin O
in O
combination O
with O
insulin O
and O
metformin O
and O
more O
commonly O
than O
in O
patients O
treated O
with O
placebo O
in O
combination O
with O
insulin O
and O
metformin O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Merck O
Sharp O
& O
Dohme O
Corp. O
, O
a O
subsidiary O
of O
Merck O
& O
Co. O
, O
Inc. O
, O
at O
1-877-888-4231 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Sitagliptin O
and O
Metformin O
Coadministration O
in O
Patients O
with O
Type O
2 O
Diabetes O
Inadequately O
Controlled O
on O
Diet O
and O
Exercise O
Table O
1 O
summarizes O
the O
most O
common O
( O
> O
=5 O
% O
of O
patients O
) O
adverse O
reactions O
reported O
( O
regardless O
of O
investigator O
assessment O
of O
causality O
) O
in O
a O
24-week O
placebo-controlled O
factorial O
study O
in O
which O
sitagliptin O
and O
metformin O
were O
coadministered O
to O
patients O
with O
type B-Not_AE_Candidate
2 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
inadequately O
controlled O
on O
diet O
and O
exercise O
. O

Table O
1 O
: O
Sitagliptin O
and O
Metformin O
Coadministered O
to O
Patients O
with O
Type O
2 O
Diabetes O
Inadequately O
Controlled O
on O
Diet O
and O
Exercise O
: O
Adverse O
Reactions O
Reported O
( O
Regardless O
of O
Investigator O
Assessment O
of O
Causality O
) O
in O
> O
=5 O
% O
of O
Patients O
Receiving O
Combination O
Therapy O
( O
and O
Greater O
than O
in O
Patients O
Receiving O
Placebo O
) O
Intent-to-treat O
population O
. O

Number O
of O
Patients O
( O
% O
) O
Placebo O
Sitagliptin O
100 O
mg O
once O
daily O
Metformin O
500 O
mg/ O
Metformin O
1000 O
mg O
twice O
daily O
[ O
note O
: O
Data O
pooled O
for O
the O
patients O
given O
the O
lower O
and O
higher O
doses O
of O
metformin O
. O
] O

Sitagliptin O
50 O
mg O
twice O
daily O
+ O
Metformin O
500 O
mg/ O
Metformin O
1000 O
mg O
twice O
daily O
N O
= O
176 O
N O
= O
179 O
N O
= O
364 O
N O
= O
372 O
Diarrhea B-OSE_Labeled_AE
7 O
( O
4.0 O
) O
5 O
( O
2.8 O
) O
28 O
( O
7.7 O
) O
28 O
( O
7.5 O
) O
Upper B-OSE_Labeled_AE
Respiratory I-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
9 O
( O
5.1 O
) O
8 O
( O
4.5 O
) O
19 O
( O
5.2 O
) O
23 O
( O
6.2 O
) O
Headache B-OSE_Labeled_AE
5 O
( O
2.8 O
) O
2 O
( O
1.1 O
) O
14 O
( O
3.8 O
) O
22 O
( O
5.9 O
) O
Sitagliptin O
Add-on O
Therapy O
in O
Patients O
with O
Type O
2 O
Diabetes O
Inadequately O
Controlled O
on O
Metformin O
Alone O
In O
a O
24-week O
placebo-controlled O
trial O
of O
sitagliptin O
100 O
mg O
administered O
once O
daily O
added O
to O
a O
twice O
daily O
metformin O
regimen O
, O
there O
were O
no O
adverse O
reactions O
reported O
regardless O
of O
investigator O
assessment O
of O
causality O
in O
> O
=5 O
% O
of O
patients O
and O
more O
commonly O
than O
in O
patients O
given O
placebo O
. O

Discontinuation O
of O
therapy O
due O
to O
clinical O
adverse O
reactions O
was O
similar O
to O
the O
placebo O
treatment O
group O
( O
sitagliptin O
and O
metformin O
, O
1.9 O
% O
; O
placebo O
and O
metformin O
, O
2.5 O
% O
) O
. O

Gastrointestinal O
Adverse O
Reactions O
The O
incidences O
of O
pre-selected O
gastrointestinal B-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
experiences I-OSE_Labeled_AE
in O
patients O
treated O
with O
sitagliptin O
and O
metformin O
were O
similar O
to O
those O
reported O
for O
patients O
treated O
with O
metformin O
alone O
. O

See O
Table O
2 O
. O

Table O
2 O
: O
Pre-selected O
Gastrointestinal O
Adverse O
Reactions O
( O
Regardless O
of O
Investigator O
Assessment O
of O
Causality O
) O
Reported O
in O
Patients O
with O
Type O
2 O
Diabetes O
Receiving O
Sitagliptin O
and O
Metformin O
Number O
of O
Patients O
( O
% O
) O
Study O
of O
Sitagliptin O
and O
Metformin O
in O
Patients O
Inadequately O
Controlled O
on O
Diet O
and O
Exercise O
Study O
of O
Sitagliptin O
Add-on O
in O
Patients O
Inadequately O
Controlled O
on O
Metformin O
Alone O
Placebo O
Sitagliptin O
100 O
mg O
once O
daily O
Metformin O
500 O
mg/ O
Metformin O
1000 O
mg O
twice O
daily O
[ O
note O
: O
Data O
pooled O
for O
the O
patients O
given O
the O
lower O
and O
higher O
doses O
of O
metformin O
. O
] O

Sitagliptin O
50 O
mg O
twice O
daily O
+ O
Metformin O
500 O
mg/ O
Metformin O
1000 O
mg O
twice O
daily O
Placebo O
and O
Metformin O
> O
=1500 O
mg O
daily O
Sitagliptin O
100 O
mg O
once O
daily O
and O
Metformin O
> O
=1500 O
mg O
daily O
N O
= O
176 O
N O
= O
179 O
N O
= O
364 O
N O
= O
372 O
N O
= O
237 O
N O
= O
464 O
Diarrhea B-OSE_Labeled_AE
7 O
( O
4.0 O
) O
5 O
( O
2.8 O
) O
28 O
( O
7.7 O
) O
28 O
( O
7.5 O
) O
6 O
( O
2.5 O
) O
11 O
( O
2.4 O
) O
Nausea B-OSE_Labeled_AE
2 O
( O
1.1 O
) O
2 O
( O
1.1 O
) O
20 O
( O
5.5 O
) O
18 O
( O
4.8 O
) O
2 O
( O
0.8 O
) O
6 O
( O
1.3 O
) O
Vomiting B-OSE_Labeled_AE
1 O
( O
0.6 O
) O
0 O
( O
0.0 O
) O
2 O
( O
0.5 O
) O
8 O
( O
2.2 O
) O
2 O
( O
0.8 O
) O
5 O
( O
1.1 O
) O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
[ O
note O
: O
Abdominal B-OSE_Labeled_AE
discomfort I-OSE_Labeled_AE
was O
included O
in O
the O
analysis O
of O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
in O
the O
study O
of O
initial O
therapy O
. O
] O

4 O
( O
2.3 O
) O
6 O
( O
3.4 O
) O
14 O
( O
3.8 O
) O
11 O
( O
3.0 O
) O
9 O
( O
3.8 O
) O
10 O
( O
2.2 O
) O
Sitagliptin O
in O
Combination O
with O
Metformin O
and O
Glimepiride O
In O
a O
24-week O
placebo-controlled O
study O
of O
sitagliptin O
100 O
mg O
as O
add-on O
therapy O
in O
patients O
with O
type B-Not_AE_Candidate
2 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
inadequately O
controlled O
on O
metformin O
and O
glimepiride O
( O
sitagliptin O
, O
N=116 O
; O
placebo O
, O
N=113 O
) O
, O
the O
adverse O
reactions O
reported O
regardless O
of O
investigator O
assessment O
of O
causality O
in O
> O
=5 O
% O
of O
patients O
treated O
with O
sitagliptin O
and O
more O
commonly O
than O
in O
patients O
treated O
with O
placebo O
were O
: O
hypoglycemia B-OSE_Labeled_AE
( O
Table O
3 O
) O
and O
headache B-OSE_Labeled_AE
( O
6.9 O
% O
, O
2.7 O
% O
) O
. O

Sitagliptin O
in O
Combination O
with O
Metformin O
and O
Rosiglitazone O
In O
a O
placebo-controlled O
study O
of O
sitagliptin O
100 O
mg O
as O
add-on O
therapy O
in O
patients O
with O
type B-Not_AE_Candidate
2 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
inadequately O
controlled O
on O
metformin O
and O
rosiglitazone O
( O
sitagliptin O
, O
N=181 O
; O
placebo O
, O
N=97 O
) O
, O
the O
adverse O
reactions O
reported O
regardless O
of O
investigator O
assessment O
of O
causality O
through O
Week O
18 O
in O
> O
=5 O
% O
of O
patients O
treated O
with O
sitagliptin O
and O
more O
commonly O
than O
in O
patients O
treated O
with O
placebo O
were O
: O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
sitagliptin O
, O
5.5 O
% O
; O
placebo O
, O
5.2 O
% O
) O
and O
nasopharyngitis B-OSE_Labeled_AE
( O
6.1 O
% O
, O
4.1 O
% O
) O
. O

Through O
Week O
54 O
, O
the O
adverse O
reactions O
reported O
regardless O
of O
investigator O
assessment O
of O
causality O
in O
> O
=5 O
% O
of O
patients O
treated O
with O
sitagliptin O
and O
more O
commonly O
than O
in O
patients O
treated O
with O
placebo O
were O
: O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
sitagliptin O
, O
15.5 O
% O
; O
placebo O
, O
6.2 O
% O
) O
, O
nasopharyngitis B-OSE_Labeled_AE
( O
11.0 O
% O
, O
9.3 O
% O
) O
, O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
( O
8.3 O
% O
, O
5.2 O
% O
) O
, O
and O
headache B-OSE_Labeled_AE
( O
5.5 O
% O
, O
4.1 O
% O
) O
. O

Sitagliptin O
in O
Combination O
with O
Metformin O
and O
Insulin O
In O
a O
24-week O
placebo-controlled O
study O
of O
sitagliptin O
100 O
mg O
as O
add-on O
therapy O
in O
patients O
with O
type B-Not_AE_Candidate
2 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
inadequately O
controlled O
on O
metformin O
and O
insulin O
( O
sitagliptin O
, O
N=229 O
; O
placebo O
, O
N=233 O
) O
, O
the O
only O
adverse O
reaction O
reported O
regardless O
of O
investigator O
assessment O
of O
causality O
in O
> O
=5 O
% O
of O
patients O
treated O
with O
sitagliptin O
and O
more O
commonly O
than O
in O
patients O
treated O
with O
placebo O
was O
hypoglycemia B-OSE_Labeled_AE
( O
Table O
3 O
) O
. O

Hypoglycemia O
In O
all O
( O
N=5 O
) O
studies O
, O
adverse O
reactions O
of O
hypoglycemia B-NonOSE_AE
were O
based O
on O
all O
reports O
of O
symptomatic O
hypoglycemia B-NonOSE_AE
; O
a O
concurrent O
glucose O
measurement O
was O
not O
required O
although O
most O
( O
77 O
% O
) O
reports O
of O
hypoglycemia B-OSE_Labeled_AE
were O
accompanied O
by O
a O
blood B-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
measurement I-OSE_Labeled_AE
< I-OSE_Labeled_AE
= I-OSE_Labeled_AE
7 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
. O

When O
the O
combination O
of O
sitagliptin O
and O
metformin O
was O
coadministered O
with O
a O
sulfonylurea O
or O
with O
insulin O
, O
the O
percentage O
of O
patients O
reporting O
at O
least O
one O
adverse O
reaction O
of O
hypoglycemia B-NonOSE_AE
was O
higher O
than O
that O
observed O
with O
placebo O
and O
metformin O
coadministered O
with O
a O
sulfonylurea O
or O
with O
insulin O
( O
Table O
3 O
) O
. O

Table O
3 O
: O
Incidence O
and O
Rate O
of O
Hypoglycemia B-OSE_Labeled_AE
Adverse O
reactions O
of O
hypoglycemia B-NonOSE_AE
were O
based O
on O
all O
reports O
of O
symptomatic O
hypoglycemia B-OSE_Labeled_AE
; O
a O
concurrent O
glucose O
measurement O
was O
not O
required O
: O
Intent-to-treat O
population O
. O

( O
Regardless O
of O
Investigator O
Assessment O
of O
Causality O
) O
in O
Placebo-Controlled O
Clinical O
Studies O
of O
Sitagliptin O
in O
Combination O
with O
Metformin O
Coadministered O
with O
Glimepiride O
or O
Insulin O
Add-On O
to O
Glimepiride O
+ O
Metformin O
( O
24 O
weeks O
) O
Sitagliptin O
100 O
mg O
+ O
Metformin O
+ O
Glimepiride O
Placebo O
+ O
Metformin O
+ O
Glimepiride O
N O
= O
116 O
N O
= O
113 O
Overall O
( O
% O
) O
19 O
( O
16.4 O
) O
1 O
( O
0.9 O
) O
Rate O
( O
episodes/patient-year O
) O
[ O
note O
: O
Based O
on O
total O
number O
of O
events O
( O
i.e. O
, O
a O
single O
patient O
may O
have O
had O
multiple O
events O
) O
. O
] O

0.82 O
0.02 O
Severe O
( O
% O
) O
[ O
note O
: O
Severe O
events O
of O
hypoglycemia B-NonOSE_AE
were O
defined O
as O
those O
events O
requiring O
medical O
assistance O
or O
exhibiting O
depressed B-OSE_Labeled_AE
level I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
loss I-OSE_Labeled_AE
of I-OSE_Labeled_AE
consciousness I-OSE_Labeled_AE
or O
seizure B-OSE_Labeled_AE
. O
] O

0 O
( O
0.0 O
) O
0 O
( O
0.0 O
) O
Add-On O
to O
Insulin O
+ O
Metformin O
( O
24 O
weeks O
) O
Sitagliptin O
100 O
mg O
+ O
Metformin O
+ O
Insulin O
Placebo O
+ O
Metformin O
+ O
Insulin O
N O
= O
229 O
N O
= O
233 O
Overall O
( O
% O
) O
35 O
( O
15.3 O
) O
19 O
( O
8.2 O
) O
Rate O
( O
episodes/patient-year O
) O
0.98 O
0.61 O
Severe O
( O
% O
) O
1 O
( O
0.4 O
) O
1 O
( O
0.4 O
) O
The O
overall O
incidence O
of O
reported O
adverse O
reactions O
of O
hypoglycemia B-OSE_Labeled_AE
in O
patients O
with O
type B-Not_AE_Candidate
2 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
inadequately O
controlled O
on O
diet O
and O
exercise O
was O
0.6 O
% O
in O
patients O
given O
placebo O
, O
0.6 O
% O
in O
patients O
given O
sitagliptin O
alone O
, O
0.8 O
% O
in O
patients O
given O
metformin O
alone O
, O
and O
1.6 O
% O
in O
patients O
given O
sitagliptin O
in O
combination O
with O
metformin O
. O

In O
patients O
with O
type B-Not_AE_Candidate
2 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
inadequately O
controlled O
on O
metformin O
alone O
, O
the O
overall O
incidence O
of O
adverse O
reactions O
of O
hypoglycemia B-NonOSE_AE
was O
1.3 O
% O
in O
patients O
given O
add-on O
sitagliptin O
and O
2.1 O
% O
in O
patients O
given O
add-on O
placebo O
. O

In O
the O
study O
of O
sitagliptin O
and O
add-on O
combination O
therapy O
with O
metformin O
and O
rosiglitazone O
, O
the O
overall O
incidence O
of O
hypoglycemia B-OSE_Labeled_AE
was O
2.2 O
% O
in O
patients O
given O
add-on O
sitagliptin O
and O
0.0 O
% O
in O
patients O
given O
add-on O
placebo O
through O
Week O
18 O
. O

Through O
Week O
54 O
, O
the O
overall O
incidence O
of O
hypoglycemia B-OSE_Labeled_AE
was O
3.9 O
% O
in O
patients O
given O
add-on O
sitagliptin O
and O
1.0 O
% O
in O
patients O
given O
add-on O
placebo O
. O

Vital O
Signs O
and O
Electrocardiograms O
With O
the O
combination O
of O
sitagliptin O
and O
metformin O
, O
no O
clinically O
meaningful O
changes B-NonOSE_AE
in I-NonOSE_AE
vital I-NonOSE_AE
signs I-NonOSE_AE
or O
in O
ECG O
( O
including O
in O
QTc O
interval O
) O
were O
observed O
. O

Pancreatitis O
In O
a O
pooled O
analysis O
of O
19 O
double-blind O
clinical O
trials O
that O
included O
data O
from O
10,246 O
patients O
randomized O
to O
receive O
sitagliptin O
100 O
mg/day O
( O
N=5429 O
) O
or O
corresponding O
( O
active O
or O
placebo O
) O
control O
( O
N=4817 O
) O
, O
the O
incidence O
of O
acute B-OSE_Labeled_AE
pancreatitis I-OSE_Labeled_AE
was O
0.1 O
per O
100 O
patient-years O
in O
each O
group O
( O
4 O
patients O
with O
an O
event O
in O
4708 O
patient-years O
for O
sitagliptin O
and O
4 O
patients O
with O
an O
event O
in O
3942 O
patient-years O
for O
control O
) O
. O

[ O
See O
Warnings O
and O
Precautions O
( O
5.2 O
) O
. O
] O

Sitagliptin O
The O
most O
common O
adverse O
experience O
in O
sitagliptin O
monotherapy O
reported O
regardless O
of O
investigator O
assessment O
of O
causality O
in O
> O
=5 O
% O
of O
patients O
and O
more O
commonly O
than O
in O
patients O
given O
placebo O
was O
nasopharyngitis B-OSE_Labeled_AE
. O

Metformin O
hydrochloride O
The O
most O
common O
( O
> O
5 O
% O
) O
established O
adverse O
reactions O
due O
to O
initiation O
of O
metformin O
therapy O
are O
diarrhea B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
/ O
vomiting B-OSE_Labeled_AE
, O
flatulence B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
discomfort I-OSE_Labeled_AE
, O
indigestion B-OSE_Labeled_AE
, O
asthenia B-OSE_Labeled_AE
, O
and O
headache B-OSE_Labeled_AE
. O

Laboratory O
Tests O
Sitagliptin O
The O
incidence O
of O
laboratory B-NonOSE_AE
adverse I-NonOSE_AE
reactions I-NonOSE_AE
was O
similar O
in O
patients O
treated O
with O
sitagliptin O
and O
metformin O
( O
7.6 O
% O
) O
compared O
to O
patients O
treated O
with O
placebo O
and O
metformin O
( O
8.7 O
% O
) O
. O

In O
most O
but O
not O
all O
studies O
, O
a O
small O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
white I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
count I-OSE_Labeled_AE
( O
approximately O
200 O
cells/microL O
difference O
in O
WBC O
vs O
placebo O
; O
mean O
baseline O
WBC O
approximately O
6600 O
cells/microL O
) O
was O
observed O
due O
to O
a O
small O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
neutrophils I-OSE_Labeled_AE
. O

This O
change O
in O
laboratory O
parameters O
is O
not O
considered O
to O
be O
clinically O
relevant O
. O

Metformin O
hydrochloride O
In O
controlled O
clinical O
trials O
of O
metformin O
of O
29 O
weeks O
duration O
, O
a O
decrease B-OSE_Labeled_AE
to I-OSE_Labeled_AE
subnormal I-OSE_Labeled_AE
levels O
of O
previously O
normal O
serum O
Vitamin I-OSE_Labeled_AE
B I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
, O
without O
clinical O
manifestations O
, O
was O
observed O
in O
approximately O
7 O
% O
of O
patients O
. O

Such O
decrease O
, O
possibly O
due O
to O
interference B-NonOSE_AE
with I-NonOSE_AE
B I-NonOSE_AE
1 I-NonOSE_AE
2 I-NonOSE_AE
absorption I-NonOSE_AE
from O
the O
B12-intrinsic O
factor O
complex O
, O
is O
, O
however O
, O
very O
rarely O
associated O
with O
anemia B-NonOSE_AE
and O
appears O
to O
be O
rapidly O
reversible O
with O
discontinuation O
of O
metformin O
or O
Vitamin O
B12supplementation O
. O

[ O
See O
Warnings O
and O
Precautions O
( O
5.5 O
) O
. O
] O

6.2 O
Postmarketing O
Experience O
Additional O
adverse O
reactions O
have O
been O
identified O
during O
postapproval O
use O
of O
JANUMET O
, O
sitagliptin O
, O
or O
metformin O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
generally O
not O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
including O
anaphylaxis B-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
cutaneous B-OSE_Labeled_AE
vasculitis I-OSE_Labeled_AE
, O
and O
exfoliative B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
conditions I-OSE_Labeled_AE
including O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
; O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
; O
hepatic B-OSE_Labeled_AE
enzyme I-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
; O
acute B-OSE_Labeled_AE
pancreatitis I-OSE_Labeled_AE
, O
including O
fatal B-NonOSE_AE
and O
non-fatal O
hemorrhagic B-OSE_Labeled_AE
and O
necrotizing O
pancreatitis I-OSE_Labeled_AE
[ O
see O
Indications O
and O
Usage O
( O
1 O
) O
; O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
; O
worsening B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
function I-OSE_Labeled_AE
, O
including O
acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
( O
sometimes O
requiring O
dialysis O
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
; O
severe O
and O
disabling O
arthralgia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
; O
bullous B-OSE_Labeled_AE
pemphigoid I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.11 O
) O
] O
; O
constipation B-OSE_Labeled_AE
; O
vomiting B-OSE_Labeled_AE
; O
headache B-OSE_Labeled_AE
; O
myalgia B-OSE_Labeled_AE
; O
pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
; O
back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
; O
pruritus B-OSE_Labeled_AE
; O
cholestatic B-OSE_Labeled_AE
, O
hepatocellular O
, O
and O
mixed O
hepatocellular O
liver I-OSE_Labeled_AE
injury I-OSE_Labeled_AE
. O

